Literature DB >> 10428942

A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

R A Smith1, G J Klarmann, K M Stray, U K von Schwedler, R F Schinazi, B D Preston, T W North.   

Abstract

A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'-deoxythymidine (AZT) and to (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10428942      PMCID： PMC89420     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  42 in total

1.  HIV-1 reverse transcription. A termination step at the center of the genome.

Authors:  P Charneau; G Mirambeau; P Roux; S Paulous; H Buc; F Clavel
Journal:  J Mol Biol       Date:  1994-09-02       Impact factor: 5.469

2.  Production of high-titer helper-free retroviruses by transient transfection.

Authors:  W S Pear; G P Nolan; M L Scott; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

3.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

4.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

6.  Identification of the amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in the pyrophosphate binding of antiviral nucleoside triphosphate analogs and phosphonoformate. Implications for multiple drug resistance.

Authors:  G J Im; E Tramontano; C J Gonzalez; Y C Cheng
Journal:  Biochem Pharmacol       Date:  1993-12-14       Impact factor: 5.858

7.  The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.

Authors:  Q Gao; Z Gu; M A Parniak; J Cameron; N Cammack; C Boucher; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  C A Boucher; N Cammack; P Schipper; R Schuurman; P Rouse; M A Wainberg; J M Cameron
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

9.  Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine.

Authors:  S F Lacey; J E Reardon; E S Furfine; T A Kunkel; K Bebenek; K A Eckert; S D Kemp; B A Larder
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

10.  Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

Authors:  P L Boyer; C Tantillo; A Jacobo-Molina; R G Nanni; J Ding; E Arnold; S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205
View more
  6 in total

Review 1.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

2.  Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Robert A Smith; Donovan J Anderson; Bradley D Preston
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 3.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

4.  Participants Switching to Second-Line Antiretroviral Therapy with Susceptible Virus Display Inferior Adherence and Worse Outcomes: An Observational Analysis.

Authors:  Lentlametse Mantshonyane; Jason Roy; Michael Z Levy; Carole L Wallis; Kathrine Bar; Catherine Godfrey; Ann Collier; Alberto LaRosa; Lu Zheng; Xin Sun; Robert Gross
Journal:  AIDS Patient Care STDS       Date:  2021-11-16       Impact factor: 5.944

5.  Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  Karidia Diallo; Maureen Oliveira; Daniela Moisi; Bluma Brenner; Mark A Wainberg; Matthias Götte
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

6.  Analysis of a comprehensive dataset of diversity generating retroelements generated by the program DiGReF.

Authors:  Thomas Schillinger; Mohamed Lisfi; Jingyun Chi; John Cullum; Nora Zingler
Journal:  BMC Genomics       Date:  2012-08-28       Impact factor: 3.969
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.